Citigroup Upgrades Integra Lifesciences to Neutral, Maintains Price Target to $38

Integra LifeSciences Holdings Corporation -0.75%

Integra LifeSciences Holdings Corporation

IART

31.82

-0.75%

Citigroup analyst Joanne Wuensch upgrades Integra Lifesciences (NASDAQ: IART) from Sell to Neutral and maintains the price target from $38 to $38.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via